The prevalence of p53 immunoreactivity in anal canal carcinoma

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1455-1457

  Indinnimeo, Marileda ^a   Cicchini, Claudia ^a   Stazi, Alessandro ^a   Limiti, Maria Rosaria ^a   Giarnieri, Enrico ^a   Ghini, Christian ^a   Vecchione, Aldo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anal neoplasms; Immunohistochemistry; p53; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; AGE; AGED; ANUS CARCINOMA; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031683507     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1455     Document Type: Article

References (14)

1. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
2. McBride OW, Merry D and Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83: 130-134, 1986.
3. Levine AJ and Momand J: Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1032: 119-136, 1990.
4. Levine AJ: p53, cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
5. Maeda K, Ogawa M, Chung YS, Kang SM, Sawada T, Onoda N, et al: Overexpression of p53 associated with tumor angiogenesis, tumor cell proliferation, and prognosis in gastric carcinoma, Oncol Rep 4: 765-768, 1997.
6. Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ and Chen KM: Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg 85: 1138-1142, 1998.
7. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small lung cancer. Cancer Res 53: 1-4, 1993.
8. Ozer E, Canda T and Kuyucuodlu F: p53 mutations in bilateral breast carcinoma. Correlation with Ki-67 expression and the mean nuclear volume. Cancer Lett 122: 101-106, 1998.
9. Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M and Guinan P: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol 67: 33-37, 1998.
10. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H and Dimopoulos MA: The prevalence of bc1-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 29: 146-154, 1998.
11. Lange D, Heyden A, Lie ES, Brandtzaeg P, Boysen M and Clausen OPF: Lack of prognostic significance for p53-overexpression and Ki-67-immunoreactivity in oral T1-2 squamous cell carcinomas. Oncol Rep 4: 737-742, 1997.
12. Avall-Lundqvist EH, Silfverward C, Aspenblad U, Nilsson BR and Auer GU: The impact of tumor angiogenesis, p53 overexpression, and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer 33: 1799-1804, 1997.
13. Kashiwagi H, Spigelman AD, Talbot IC and Phillips RKS: Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Br J Surg 83: 225-228, 1996.
14. Ross DA and Wilson GD: Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma. Br J Surg 84: 803-807, 1997.